DBD Search
Irit Ben-Chelouche
Director of Business Development, Harvard Medical School
Displaying: 11 - 20 of 80 Results
Invention
Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers
DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…
Investigators
- David R. Liu
Invention
Modulating the Blood-Brain Barrier (BBB) to enable delivery of drugs and development of therapeutics
The blood–brain barrier (BBB) helps maintain a constant, optimal environment for neuronal function through a combination of barriers and selective transport systems that regulate the passage of wanted and unwanted molecules. While important for…
Investigators
- Chenghua Gu
Invention
Anti-cancer Therapeutic Strategy Targeting Ammonium Metabolism
Cancer has long been recognized as a disease of altered cellular metabolism as cancer cells have an abnormally high demand for nutrients to support their growth and proliferation. However, targeting cancer cell metabolism has not been seriously…
Investigators
- Marcia C. Haigis
- Jessica Brooke Spinelli
Invention
Hba-a1 knockout mice
Homozygous Hba-a1 (hemoglobin alpha, adult chain 1) knockout mice (129S-Hba-a1tm1Led/J) were developed by HHMI Investigator Dr. Philip Leder and his lab at Harvard Medical School. While the mice are viable and fertile, they develop anemia with…
Investigators
- Philip Leder
Invention
Trpa1 conditional knockout mice
The mouse strain 129S-Trpa1tm2Kykw/J was developed by Kelvin Kwan in the laboratory of HHMI Investigator David Corey at Harvard Medical School. Trpa1 conditional knockout animals were generated by flanking the exons that code for the pore domain of…
Investigators
- Kelvin Y. Kwan
- David P. Corey
Invention
TRPA1 knockout mice developed in the laboratory of Professor David Corey
Homozygous Transient Receptor Potential Cation Channel Subfamily A Member 1 (TRPA1) mutant mice (B6;129P-Trpa1tm1Kykw/J, also known as Trpa1 KO) were developed by HHMI Investigator David Corey at Harvard Medical School. They exhibit abnormal…
Investigators
- David P. Corey
Invention
Targeting fatty acid oxidation for treatment of cancer, including AML, prostate, breast and colon cancers
Several cancers are characterized by slow glycolysis and rely on non-glycolytic pathways such as fatty acid oxidation (FAO) as their main source of energy. While dependency of cancer cells on FAO has been known, the underlying mechanistic…
Investigators
- Marcia C. Haigis
Invention
Intracellular delivery of proteins: Aurin 1.2, an efficient non-endosomal protein delivery platform
To fully realize the therapeutic potential of proteins, exogenous proteins need to access intracellular targets. Since the vast majority of proteins cannot spontaneously cross cell membranes, a range of delivery platforms have been developed. These…
Investigators
- David R. Liu
Invention
Using evolutionary coupling methodology and other unique computational biology tools to advance pharmaceutical development
The prediction of drug effects is a long-standing challenge in the biomedical data community and pharmaceutical industry. As new candidate target genes emerge from successful CRISPR and GWAS screens, assessing ‘anti-targets’ and exploiting…
Investigators
- Debora Marks
Invention
Liquid biopsy-based predictive platform for early cancer detection and drug discovery
Recognition and management of individuals susceptible to disease are critical for patient care. However, identification of these patients is very challenging, especially in oncology. Dr. Peter Park and his group at the Department of Biomedical…
Investigators
- Peter Park